Overview: Biotinidase Activity TestIntroduction: The Biotinidase Activity Test measures enzyme activity to diagnose biotinidase deficiency, causing skin rashes, seizures, or developmental delays. Following 2023 ACMG guidelines, it uses PCR for high specificity, aiding in metabolic screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected metabolic disorders.
Other Names: Biotinidase Enzyme Assay, Metabolic Deficiency Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Biotinidase testing began in the 1980s with newborn screening programs. PCR-based assays emerged in the 1990s, and by the 2000s, molecular techniques improved deficiency detection.
Purpose: Diagnoses biotinidase deficiency, guides biotin supplementation, and monitors enzyme activity in patients with skin rashes or developmental delays.
Test Parameters: 1. Biotinidase Activity
Pretest Condition: No fasting required. Collect whole blood, serum, or plasma at any time. Report symptoms like seizures or developmental delays, and list medications like biotin supplements.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL serum (SST), or 2-4 mL plasma (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neurological symptoms, skin rashes, or family history of metabolic disorders. Include current medications, especially biotin or anticonvulsants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for biotin therapy.
Procedural Considerations: Uses PCR to measure biotinidase enzyme activity. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade enzyme activity. Biotin supplements may mask deficiency.
Clinical Significance: Low biotinidase activity confirms deficiency, prompting lifelong biotin supplementation. Normal activity suggests alternative diagnoses.
Specialist Consultation: Consult a medical geneticist for result interpretation. A neurologist referral is advised for seizure management.
Additional Supporting Tests: Biotinidase newborn screen, plasma amino acids, or genetic testing to confirm deficiency or assess metabolic status.
Test Limitations: False negatives may occur with recent biotin supplementation. Results require clinical correlation.
References: ACMG Newborn Screening Guidelines, 2023; Journal of Inherited Metabolic Disease, Wolf B, 2022.
